Pharmacotherapy of diabetes mellitus in patients with heart failure-a nation-wide analysis of contemporary treatment

VICHA, Marek, Tomas SKALA, Libor JELINEK, Ludek PAVLU, Jiří JARKOVSKÝ, Ladislav DUŠEK, Klára BENEŠOVÁ and Milos TABORSKY. Pharmacotherapy of diabetes mellitus in patients with heart failure-a nation-wide analysis of contemporary treatment. Biomedical Papers, Olomouc: Palacky University. Olomouc: Palacky University, 2023, vol. 167, No 2, p. 177-184. ISSN 1213-8118. Available from: https://dx.doi.org/10.5507/bp.2021.069.

Basic information

• Original name: Pharmacotherapy of diabetes mellitus in patients with heart failure-a nation-wide analysis of contemporary treatment
• Authors: VICHA, Marek (203 Czech Republic), Tomas SKALA (203 Czech Republic, guarantor), Libor JELINEK (203 Czech Republic), Ludek PAVLU (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution) and Milos TABORSKY (203 Czech Republic).
• Edition: Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2023, 1213-8118.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30104 Pharmacology and pharmacy
• Country of publisher: Czech Republic
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 0.900 in 2022
• RIV identification code: RIV/00216224:14110/23:00129948
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.5507/bp.2021.069
• UT WoS: 000731342200001
• Keywords in English: diabetes mellitus; heart failure; pharmacotherapy; National Register of Paid Health Services (NRHZS)
• Tags: 14119612, rivok
• Tags: International impact, Reviewed

Abstract

Aim. Retrospective national sub-analysis of antidiabetic pharmacotherapy in patients with diabetes mellitus (DM) and heart failure (HF) based on data reported to the National Register of Paid Health Services in the Czech Republic between 2012-2018. Methodology and Results. In 2012, there were 75,022 patients with HF and DM (i.e. 42.5% of patients with HF), 6 years later 117,265 (i.e. 41.0% of HF patients in 2018). The most represented antidiabetic drug was metformin (45.6%). Of the insulins and analogues, glargine showed the largest positive trend (5.8% 2012; 14.8% 2018). Empagliflozin was the most prescribed SGLT-2 inhibitor (1.8% in 2018). A decrease in prescribing was observed for saxagliptin (0.5% 2012; 0.1% 2018) and for sulfonylurea derivates - gliclazide (13.0% 2012; 10.3% in 2018) and glimepiride (12.9% 2012; 9.0% 2018). Linagliptin was the most prescribed dipeptidyl peptidase inhibitor (0.7% 2012; 6.8% 2018). Conclusion. In the Czech Republic, between 2012 and 2008, there was an increase in prevalence of patients with heart failure and concomitant diabetes mellitus, their proportion being similar. In correspondence with other registries, metformin was used mostly. A positive trend was observed in prescription of DDP-4 and SGLT-2 inhibitors, while there was a significant decrease in patients taking sulfonylureas.